Kendra Kobrin and Jonathan Freedman Receive the 2017 Joseph Cochin Award in Pharmacology and Medical Ethics Award
At the Student Award Ceremony on Match Day, March 17th, Kendra Kobrin and Jonathan Freedman were awarded the 2017 Joseph Cochin Award in Pharmacology and Medical Ethics. This award honors the memory of Joseph Cochin, MD, PhD, who served as Professor of Pharmacology and Experimental Therapeutics at BUSM for many years. Dr. Cochin was an internationally recognized expert on opioid analgesia, pain control and medical ethics.
Kendra, a student in the Biomolecular Pharmacology Training Program from 2011-2015, received this award in recognition of her high achievement in pharmacology and accomplishments in research under the mentorship of Gary B. Kaplan, M.D., Professor of Psychiatry and Pharmacology & Experimental Therapeutics.
Jonathan Freedman, also a student in the Biomolecular Pharmacology Training Program from 2011-2015, was rewarded for his high achievement in pharmacology and research accomplishments under the mentorship of Mark W. Grinstaff, Ph.D., Distinguished Professor of Translational Research, Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine.
Kendra and Jonathan will receive their MD and PhD degrees at the BUSM May Graduation Ceremony.
Congratulations to Kendra and Jonathan!
Brandon Maziuk Selected by the BU BEST Program as BU Representative to the AAAS CASE Workshop in Washington, DC
Brandon Maziuk, a Program in Biomolecular Pharmacology PhD graduate student, has been selected as one of two students by the Boston University Broadening Experiences in Scientific Training (BEST) program to represent Boston University at the AAAS Catalyzing Advocacy for Science and Engineering (CASE) Workshop in Washington, DC, April 2-5, 2017. Brandon was chosen from a pool of BEST applicants.
Now in the 3rd year of his pre-doctoral training, Brandon is conducting his thesis research in the Laboratory of Neurodegeneration under the mentorship of Benjamin Wolozin, MD, PhD, Professor of Pharmacology and Neurology. His research projects focus on the role of RNA binding proteins in neurodegenerative disorders with emphasis on tauopathy and Alzheimer’s disease. Using a variety of molecular techniques with mouse models, cell culture systems and human tissues he investigates how RNA binding protein aggregation drives early neurodegeneration.
The CASE workshop provides an opportunity for undergraduate and graduate students in science, mathematics, and engineering, to learn about science policy and advocacy. At the workshop, Brandon will have the opportunity to learn about effective science communication and meet with elected Members of Congress as a science advocate. As a BEST program representative, Boston University will cover transportation, lodging and registration costs to attend the CASE workshop.
Congratulations to Brandon on being selected for this honor.
Benjamin Wolozin, M.D., Ph.D., Professor of Pharmacology and Neurology at Boston University School of Medicine, has been named a Fellow of the American Association for the Advancement of Science (AAAS). He was elected for his contributions to molecular and translational neuroscience, particularly discovery of the role of cholesterol in Alzheimer’s disease.
On January 26, 2017, Dr. Karen Antman, BUSM Dean and BUMC Provost announced that Dr. Wolozin is the recipient of the Jack Spivack Excellence in Neurosciences Award for 2017. His discovery of the essential role of RNA Binding proteins in the pathology of tauopathies, including Alzheimer’s disease, represents a paradigm shift in our understanding of these diseases. With this discovery comes dramatic new opportunities for therapeutic interventions for Alzheimer’s disease and other tauopathies, based on targeting important members of the translational stress response, such as TIA1.
Congratulations to Ben!
Alissa Frame received the Best Poster Award at the American Heart Association’s Council on Hypertension 2016 Scientific Sessions in Orlando, Florida, September 14 – 17, 2016. Alissa’s poster, “Impaired Central, Renal, and Blood Pressure Responses to Alterations in Fluid and Electrolyte Homeostasis in Aged Sprague-Dawley Rats,” was selected from over 600 posters, which is quite a feat for her first poster presentation at a national meeting.
Alissa is an M.D., Ph.D. graduate student in the NIGMS sponsored training program in Bimolecular Pharmacology and is conducting her predoctoral research on the neural and renal mechanisms regulating blood pressure in the Laboratory for Cardiovascular Renal Research under the mentorship of Richard D. Wainford, Ph.D.
Congratulations to Alissa!
Congratulations to Price S. Blair, Ph.D., has who received the Edward A. Polloway Award for Excellence in Graduate Teaching at Lynchburg College. Dr. Blair, shown with his wife Beverly, is an Assistant Professor in the Departments of Biology and Biomedical Science, the Doctor of Physical Therapy Program, and Physician Assistant in Medicine Program. He received his Ph.D. in 2008 from the Program in Bimolecular Pharmacology under the mentorship of Jane E. Freedman, M.D. His current research focuses on the role that platelets play in the processes of hemostasis, thrombosis, and inflammation.
Congratulations to Rebecca Benham Vautour, Ph.D., on being selected for the ASPET Washington Fellows Program [HPA]. Dr. Benham Vautour, a post-doctoral fellow in the Laboratory of Genetic Neuropharmacology at McLean Hospital, is one of 10 selected from across the U.S. to participate in this program. She graduated from with a Ph.D. in Pharmacology and Neuroscience from the Program in Biomolecular Pharmacology at Boston University School of Medicine in 2012. As a graduate student in the Laboratory of Translational Epilepsy under the mentorship of Dr. Shelley J. Russek, Dr. Benham Vautour’s graduate research thesis was on bdnfAND jak/stat: Partners in Seizure-Induced GABA-A Receptor Down Regulation.” Her research at McLean’s focuses on the role of GABA-A in depression.
Neema Yazdani, a Program in Biomolecular Pharmacology Ph.D. graduate student, has be selected to present a platform presentation at the Tuesday, November 10, 2015 Genome Science Institute’s (GSI) Annual Research Symposium. Neema’s presentation is entitled, ‘HnRNP H1 regulates the stimulant and addictive properties of methamphetamine: Transcriptomic and spliceomic analyses uncover novel neurodevelopmental mechanisms” and is based upon the research he is carrying out in the Laboratory of Addiction Genetics in the Department of Pharmacology & Experimental Therapeutics under the mentorship of Dr. Camron Bryant.
The GSI symposium will be held in Hiebert Lounge, L-14th Floor in the School of Medicine from 12:00 to 5:00 p.m. and will include both poster sessions from 12:30 to 2:30 p.m. and platform presentations from 2:30 to 4:30 p.m. The awards ceremony will immediate follow the platform presentations.
Congratulations to Sanghee Lim on being awarded a 2015 Medical Student Research Grant from the Melanoma Research Foundation for his proposal, “Defining Novel Mechanisms of Genome Instability in Melanoma.” The Medical Student Research Grant is awarded for a one-year period in order “to provide opportunities and funding for medical students to engage in short clinical or laboratory-based research projects focused on better understanding the biology and treatment of melanoma.” Sanghee is one of six medical students who received the nationally competitive award this year.
An MD/PhD student Program in Biomolecular Pharmacology, Sanghee is working under the guidance of Dr. Neil Ganem, Assistant Professor of Pharmacology & Experimental Therapeutics and Medicine, in the Laboratory of Cancer Cell Biology at the Shamim and Ashraf Dahod Breast Cancer Research Laboratories. His work is aimed at defining the mechanisms that give rise to chromosome instability in human melanoma. In particular, Sanghee is testing whether activating mutations in the oncogene BRAF, which occur in ~80% of all melanomas, directly promote mitotic defects.
Great job, Sanghee! Keep up the great work.
Neema Yazdani is one of two graduate students selected for the 2015 “Outstanding Graduate Student Travel Award” for the 17th Annual International Behavioral and Neural Genetics Society (IBANGS) Meeting in Uppsala, Sweden. Neema is a third year PhD candidate and Program in Biomolecular Pharmacology student in the Laboratory of Addiction Genetics under the mentorship of Camron D. Bryant, Ph.D., Assistant Professor of Pharmacology and Psychiatry. As a recipient of this award, Neema is invited to present his research as an oral presentation titled, “Hnrnph1 is a quantitative trait gene for methamphetamine sensitivity”. Neema’s efforts in generating and phenotyping TALENs-targeted Hnrnph1 knockout mice combined with striatal transcriptome analysis via RNA-seq led to the identification of Hnrnph1 as a novel quantitative trait gene involved in the stimulant response to methamphetamine. His transcriptome results suggest that Hnrnph1 could regulate the neural development of the mesocorticolimbic circuitry which would have widespread implications for understanding the etiology of a variety of neurobiological disorders involving a dysregulation of dopamine transmission.
Junior faculty arrive at Boston University full of ambition and with a head full of ideas, but they often have relatively little money for research. So being awarded a Peter Paul Career Development Professorship can feel like winning the lottery; winners receive an annual stipend of $40,000 for three years to pursue their research interests.
For some, it can even seem too good to be true.
“Once I received the email, I asked if they had the right Professor Gonzales,” says Ernest Gonzales, a School of Social Work assistant professor of human behavior. Gonzales, who had no idea that he had been nominated for the award, says the reply from the provost’s office was immediate: “Yes, Ernest, it’s you!”
Peter Paul Professorships were also awarded to Rachel Flynn, a School of Medicine assistant professor of pharmacology and experimental therapeutics, and to Jacob Bor, a School of Public Health assistant professor of global health at the Center for Global Health & Development. University trustee Peter Paul (GSM’71) created the professorships named for him in 2006 with a $1.5 million gift, later increased to $2.5 million. Jean Morrison, BU provost, and President Robert A. Brown select recipients from faculty who are holding their first professorship, have arrived within the last two years, and have been recommended by deans and department chairs.
“It is a privilege to witness the development of talented young scholars into outstanding teachers and researchers,” says Morrison. “From the discovery of novel new cancer treatments and effective approaches to the HIV epidemic to improving conditions for an aging workforce, Professors Bor, Flynn, and Gonzales are fulfilling—and in many ways exceeding—the promise we saw in them when they joined the BU community. We are enormously proud of the important work they’re performing and excited to help advance their research careers.”
Gonzales, who earned a doctorate from Washington University in St. Louis, arrived at the University in July 2013. He is still thinking about how to use the award. He currently juggles several interdisciplinary research projects that focus on productive aging, structural discrimination in and outside of the workforce, and “unretirement”—the practice of retirees returning to work.
His initial findings suggest that the groups most vulnerable to ageism are workers under 30 and those 55 and older. Employees who fall within these ranges face social exclusion and questions about their professionalism or competence. Gonzales is also examining how early life experiences can predict difficult work trajectories later in life. Someone who enters the workforce at 17 with a high school diploma will likely work more physically demanding jobs—such as construction and manufacturing—that wear on their bodies and make it difficult to remain in the workforce long-term.
Gonzales also compares US practices to those in European countries, like Germany, where Chancellor Angela Merkel’s government recently enacted a policy that allows people who have worked 45 years to retire with full benefits. He believes these individuals will relax, recuperate, and eventually return to the workforce—a theory he’s calling “Triple R.”
“I think we have a lot to learn from other nations,” says Gonzales, who would like to conduct cross-national research to see how this and other productive aging policies affect workers’ health and economic standing, with the eventual goal of proposing policy and legislation in the United States.
Flynn, who earned a doctoral degree in cancer biology from the University of Massachusetts Medical School, has been at BU since June 2013. She studies the role telomeres, repetitive DNA sequences that cap the ends of chromosomes, play in cancer development. Each time a cell divides, Flynn says, it loses a chunk of telomere instead of more essential genes further upstream. When telomeres get too short, cells either stop growing or die.
“That is the aging process,” she says. But cancer cells have a way to “highjack this mechanism. When a telomere starts to get shorter, cancer outsmarts it” by reactivating the mechanism that keeps it growing forever.
Telomeres maintain their length using two pathways. Flynn’s lab studies the pathway used by osteosarcoma and glioblastoma—rare and lethal cancers of the bone and brain—and hopes to identify novel treatments that would target this highjacked pathway to better manage the cancers.
So far, Flynn has seen promising results. One compound she’s testing in vitro doesn’t just stop cancer cells from growing, but completely obliterates them—and with minimal effects to surrounding healthy cells. The next step is to test the compound in mouse models.
“If it works as well as it does in a dish, it’ll be amazing,” she says.
Flynn will use the award to hire lab personnel and to buy reagents. “It’s a tremendous opportunity to represent Peter Paul and have money to build my lab,” she says, “but the real goal is to raise the bar, to elevate cancer research at BU.”
Bor, who earned a doctorate at the Harvard University School of Public Health, came to BU in September 2013. He applies the tools of microeconomic models and natural experiments to the field of public health.
“Economics puts an emphasis on the individual; each person is making the best decision for themselves,” Bor says. “At least, that’s the theory.” He looks at decision-making and behavior in a larger economic context to determine what effects they have on health.
Across southern Africa, there’s an elevated HIV infection rate for young women. There are also “high levels of transactional sex,” Bor says. “Maybe if we can expand the choice set of young women so that they can make the best decisions for themselves, we can give them economic opportunities to avoid these relationships.”
In Botswana, he says, the government changed the structure of secondary school so that young women were encouraged to attend. The move resulted in a decrease in HIV infections within that population, he says.
With the award, Bor plans to recruit more doctoral students and research assistants to tackle the papers he’s been dreaming of writing, especially on questions related to South Africa’s HIV treatment program.
“The goal is to rigorously turn these out,” Bor says, “and the faster we do so, the better monies are allocated and the more lives can be saved.”Original article posted on BU Today.